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Abstract 
One side effect of SSRI medication is emotional blunting, characterized by a restricted 
range of emotions and decreased caring.  Because omega-3 supplements also have 
established antidepressant properties, they might also induce emotional blunting.  
Participants were randomized to receive omega-3 supplements or pill placebos for three 
weeks.  Emotional blunting was evaluated via three assessment strategies: scores on an 
emotional blunting questionnaire, emotional reactions to a dysphoric mood induction, and 
daily mood ratings.  As hypothesized, participants in the omega-3 group scored 
significantly higher on the emotional blunting questionnaire, with an effect size in the 
moderate range.  They also scored significantly higher on 3 of the questionnaire’s 4 
subscales.  However, omega-3 supplementation was not associated with a reduced 
emotional response to the mood-induction, nor with any reduction in the variability of 
daily mood ratings.  These findings suggest that healthy individuals taking omega-3 
supplements may experience moderate blunting in a subset of emotion-linked domains. 
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Omega-3 Supplementation and Emotional Blunting: A Placebo-Controlled Investigation 
 
Four of the five most commonly prescribed antidepressant medications in the U.S. 
are selective serotonin reuptake inhibitors (SSRIs) (Drug Topics Staff, 2010a, 2010b).  
However, side effects of SSRIs – including nausea, headaches, sleep disturbances, and 
sexual dysfunction – are common, and they frequently result in discontinuation of the 
medication (Beasley, Koke, Nilsson & Gonzales, 2000).  Another potential side effect of 
these medications, albeit one which has received relatively little research attention, is 
emotional blunting.  For example, Daly et al. (2011) observed that 27 out of 265 
individuals reported adverse effects of apathy from SSRI use.  Apathy may be related to 
part of the construct of emotional blunting focused on decreased caring.  Despite the fact 
that emotional blunting is commonly reported by patients and could have life-changing 
implications, many patients are never informed about the possibility of experiencing this 
particular side effect (Opbroek et al., 2002).   
 One complication of investigating the phenomenon of emotional blunting is the 
lack of a clearly defined construct across studies.  Price, Cole, and Goodwin (2009), for 
example, define emotional blunting as experiencing “a restricted range of emotions that 
are a normal part of everyday life.”  Another name for this phenomenon is 
“Antidepressant Apathy Syndrome”.  Marin (1990) defined apathy as, “diminished 
motivation not attributable to diminished level of consciousness, cognitive impairment, or 
emotional distress,” and differentiated apathy that is due to depression from apathy that is 
not due to depression.  Marin hypothesized that apathy in depressed individuals is often 
illustrated by physical and social inactivity, decreased interest in activities, and internal 
emotional disturbance, whereas apathy that is not associated with depression is often 
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characterized by indifference, lack of motivation, poor attention, and disinhibition 
(Marin, 1990).  In a somewhat related vein, another research group (Barnhart, Makela, & 
Latocha, 2004) has hypothesized that apathy in depression is associated with fatigue, 
whereas apathy associated with SSRIs is not.  Finally, the construct of interest has also 
been referred to as “Amotivational Syndrome” which is defined by “apathy, lack of 
motivation, lack of appropriate concern, and in some cases disinhibition” (Garland & 
Baerg, 2001).  Although these articles use different names and have some differences in 
definition, they all approach a similar construct, which will be referred to in this article as 
emotional blunting. 
Emotional blunting is an important side effect of SSRIs, with a broad range of 
positive and negative implications.  Many individuals with depression initially welcome 
SSRI-induced blunting of negative emotions and pain they have been experiencing.  In 
fact, severely depressed individuals can sometimes experience an increase in their ability 
to function after the intensity of their negative emotions decreases (Price, Cole, & 
Goodwin, 2009).  However, there are also many deleterious effects of emotional blunting.  
The first is the obvious inability to feel the full range of “normal” affect, particularly 
positive emotions.  Some blunted individuals also report feeling detached from their 
emotions and “just not caring” about important aspects of their life, such as their job or 
relationships.  Such reductions in positive emotions constitute a commonly reported 
reason why individuals discontinue the use of SSRIs to treat their depressive symptoms. 
(Price, Cole, & Goodwin, 2009).   
Among clinicians, SSRI-induced emotional blunting is becoming an increasingly 
well-recognized phenomenon.  Case reports by Hoehn-Saric, Lipsey, and McLeod (1990) 
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describe emotional blunting in patients taking Fluvoxamine and Fluoxetine for depression 
and panic disorder, while other case reports describe similar symptoms in patients taking 
a variety of SSRIs for depression, anxiety, and OCD (Garland & Baerg, 2001; George, 
Trimble, & Robertson, 1993).  One study by Opbroek et al. (2002) observed that 80% of 
participants in a study of SSRI-induced sexual dysfunction also reported the blunting of 
some emotions.  This study investigated several domains of emotional blunting, and 
found that the most frequently altered emotions were related to sexual desire, the ability 
to cry, motivation, and creativity.  Several other case studies have also documented that 
SSRIs may reduce one’s ability to cry (Oleshansky & Labbate, 1996).   
It is often difficult, however, to differentiate emotional blunting from the apathy 
present in depression.  Nevertheless, many individuals taking SSRIs claim to be capable 
of differentiating the two phenomena (Price, Cole, & Goodwin, 2009).  It has been found 
that the effect of emotional blunting can be reduced by titrating the dose of medication to 
a level that is still helpful for treating depression but that causes fewer emotional side 
effects (Hoehn-Saric, Lipsey, & McLeod, 1990).  One relevant case study describes an 
SSRI-treated OCD patient who had changes in cerebral blood flow similar to those seen 
in frontal lobe syndrome, which is itself characterized by decreased motivation (Hoehn-
Saric, Harris, Pearlson, & Cox, 1991).  Another case study described a patient prescribed 
an SSRI for OCD and Tourette’s syndrome who experienced severe apathy and 
indifference, but not depression (George, Trimble, & Robertson, 1993).  Emotional 
blunting does not only affect adults: Garland and Baerg (2001) also documented similar 
effects in four adolescents and one child.  Although emotional blunting does have some 
overlap in symptoms with depression, the aforementioned studies illustrate that emotional 
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blunting can exist as a phenomenon independent from depression – one that can be 
caused by SSRIs. 
The neurological mechanisms that underlie emotional blunting are currently 
unknown.  SSRIs are believed to treat depression by increasing the functional activity of 
serotonergic circuits in the brain, which may in turn induce beneficial changes such as a 
reduction in the brain’s stress response (Nemeroff & Owens, 2004), increased social 
drive (Warwick et al., 2012), decreased intensity of emotional pain (Matsuzawa-
Yanagida et al., 2008), and more restorative sleep (Nakamaru‐Ogiso et al., 2012). But 
how might serotonergic drugs also induce emotional blunting?  One hypothesis is that the 
serotonin-based circuits that connect the raphe nuclei to the frontal lobe are capable of 
inhibiting not only negative emotions, but positive emotions as well, inasmuch as the 
frontal lobe is crucial in the regulation of both motivation and emotional valence.  
Emotional blunting could be caused in part by the downstream effects of serotonin on the 
dopamine system, as well, although this mechanism is not yet fully understood. 
(Barnhart, Makela, & Latocha, 2004)   
Several studies have also shown that SSRIs can cause changes in the processing 
of emotional material.  For example, Harmer, Mackay, Reid, Cowen, and Goodwin 
(2006) found that negative facial expressions are processed differently after a week of 
antidepressant medication.  Specifically there is a reduced recognition of fearful facial 
expressions.  Another study also showed a decreased response to sad facial expressions 
after eight weeks of SSRIs (Fu et al., 2004).  These findings are consistent with reported 
experiences of emotional blunting and could explain symptoms of emotional blunting 
such as reduced concern or caring for others if individuals on SSRIs are unable to 
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recognize expressions of sadness or fear in others.  Another recent study found healthy 
participants given SSRIs showed diminished neural responses to aversive and rewarding 
stimuli (chocolate and rotten strawberries) on an fMRI (McCabe, Mishor, Cowen, & 
Harmer, 2010).  This decrease in responsiveness to both positive and negative stimuli is 
consistent with reported experiences of emotional blunting.   
There is a growing body of research on another treatment for depression that is 
associated with relatively few side effects: omega-3 fatty acids.  Omega-3s, in fact, are 
becoming increasingly popular in the treatment of depression (Gören & Tewksbury, 
2011).  Several recent reviews and meta-analyses have provided support for the efficacy 
of omega-3 supplements in the treatment of depression (Parker et al., 2006; Ross, Seguin, 
& Sieswerda, 2007; Martins, 2009; Sublette, Ellis, Geant & Mann, 2011). The effects of 
omega-3s are commonly seen within four weeks of treatment.  One study of omega-3 
supplements for treatment of individuals with depression reported a statistically 
significant difference between the omega-3 condition and placebo condition after two 
weeks, and a “highly significant difference” between groups at weeks three and four 
(Nemets, Stahl & Belmaker, 2002).   
With low omega-3 intake there may be a loss of function in both serotonin and 
dopamine systems due to the absence of the essential fatty acids needed to support these 
systems.  Omega-3s also have anti-inflammatory properties, and they can decrease 
inflammation in the brain caused by the activation of the brain’s stress response in 
depression. (Ilardi, 2009)  It is not currently known whether or not the primary benefit of 
omega-3 supplements is a result of their effect on the serotonin system or their anti-
inflammatory properties.  The potential similarities in mechanisms between omega-3 
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supplements and SSRIs suggest that it is possible for emotional blunting side effects to 
also be caused by omega-3 supplements.  
The potential of emotional blunting as a side effect of omega-3 supplementation 
has not previously been investigated.  In addition to the hypothesized similarity in 
mechanisms between SSRIs and omega-3s, anecdotal reports also support this as a 
possibility.   Antypa, Van der Does, Smelt, and Rogers (2009) observed that healthy 
individuals who took omega-3 supplements for four weeks made more risky decisions 
than did a placebo group on a risky decision-making task, a finding that may suggest an 
increase in disinhibition with omega-3 supplementation.  The same study also found 
decreased scores on a control/perfectionism scale, possibly supporting the decreased level 
of caring associated with emotional blunting.  If emotional blunting is a potential side 
effect of omega-3 supplements, it is important for individuals to be made aware of this 
when considering their use for treatment of depression or other conditions. 
 The primary aim of the present study, therefore, is to examine the effect of 
omega-3 supplements on emotional blunting, and specifically to test the hypothesis that 
omega-3 supplements may increase emotional blunting, as compared to the effects of a 
pill placebo.  Given the inherent difficulty of investigating a relatively new construct, I 
used three different methods to test this hypothesis:   
1. I compared the differences in emotional blunting after 3 weeks of taking an 
omega-3 supplement or pill placebo on the OQuESA, a new self-report measure 
specifically designed for the purpose of assessing emotional blunting in the 
context of treatment.  I expected to find that OQuESA scores for the omega-3 
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group would be significantly higher than OQuESA scores for the placebo group at 
the end of three weeks.  
2.  I compared differences in reactivity to a mood induction after the 3 weeks of pills 
using the MAACL-R.  I expected to find that MAACL-R scores for the omega-3 
group would be significantly lower than the MAACL-R scores for the placebo 
group, thereby illustrating decreased emotional reactivity.   
3. I used daily mood ratings of positive and negative mood to compare the 
variability in mood over the course of three weeks for members of each group.  I 
expected to find a significant decrease in mood variability over time for the 
omega-3 group compared to the control group.   
Method 
 
Participants 
 
 Participants were 117 undergraduate students (33 men, 84 women) who ranged in 
age from 17 to 23 (M = 18.66, SD = 1.01).  The majority of participants described their 
racial identification as Caucasian (83%).  Participants were enrolled in an introductory 
psychology course and participated in this study in exchange for course credit.  Exclusion 
criteria for this study included: (a) the presence of a current depressive episode, as 
indicated by a BDI-II score of >13; (b) being pregnant or nursing; (c) a self-reported 
diagnosis of diabetes or a bleeding disorder; (d) a self-reported current diagnosis of major 
depressive disorder or bipolar disorder; (e) known or suspected allergies to omega-3 
supplements or pill placebo ingredients (gelatin and mineral oil); (f) current use of 
omega-3 supplements; or (g) current use of any psychoactive medications, including 
antipsychotics, antidepressants, anxiolytics, or stimulants.   
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Measures 
 Beck Depression Inventory-II (BDI-II).  The BDI-II (Beck, Steer, & Brown, 1996) 
is a 21-item questionnaire designed to assess the current presence and severity of 
depressive symptoms.  Individuals are asked to rate the items based on how they have 
been feeling within the past two weeks on a scale from 0 to 3, with 3 being the most 
severe.  The cutoffs for scores include: 0-13 for minimal depression, 14-19 for mild 
depression, 20-28 for moderate depression, and 28-63 for severe depression.  The BDI-II 
has a high internal consistency with a reported alpha of 0.91 (Beck, Steer, Ball & Ranieri, 
1996) and a high test-retest reliability, r = 0.93 (Beck, Steer, & Brown, 1996). 
 Oxford Questionnaire of the Emotional Side-effects of Antidepressants 
(OQuESA).  The OQuESA (Price, Cole, Doll & Godwin, 2012) is a 26-item questionnaire 
designed to assess blunting of emotional experiences.  The OQuESA is divided into three 
sections.  Section 1 consists of 12 items that ask the respondents to rate their emotional 
experiences during the past week on a five-point Likert scale.  Section 2 consists of 8 
items that ask respondents to compare their emotional experiences during the past week 
with their experiences before beginning antidepressant medication on a five-point Likert 
scale.  Section 3 consists of 6 items that ask respondents to rate their beliefs about the 
emotional side effects of their antidepressant medication on a five-point Likert scale.  
Four dimensions can be scored, including general reduction in emotions, reduction in 
positive emotions, emotional detachment from others, and not caring.  A total score can 
be computed by adding the scores from all four dimensions.  The OQuESA has a high 
internal consistency, with a total score alpha of 0.93 and a high total score test-retest 
reliability, r = 0.90 (Price, Cole, Doll & Goodwin, 2012).   For the purposes of the 
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current study, all references to “antidepressants” or “current illness/problem” in the 
questionnaire were replaced with “capsules” to refer to the Omega-3 supplement or pill 
placebo. 
  Multiple Affect Adjective Check List—Revised (MAACL-R).  ). The MAACL-R 
(Lubin & Zuckerman, 1999) is a self-report instrument designed to measure an 
individual’s current affect. The measure consists of 132 items, all of which are adjectives 
measuring positive or negative affect.  Participants are asked to check the items that 
describe how they feel in the moment. The dysphoria composite score is obtained by 
adding scores from the Anxiety, Depression, and Hostility scales. Because the checklist is 
designed to assess current mood state, it has low test-retest reliability by nature, but 
acceptable internal consistency (α = .75-.90) (Maloni, Chance, Zhang & Cohen 1993).  
Procedure 
 Participants were recruited through the mass testing procedure of introductory 
psychology students at a large university in the Midwestern United States.  After the 
initial screening process, individuals who met the initial study criteria were invited to the 
lab to participate in the study.  Upon arrival, participants were informed that they would 
be participating in an experiment to investigate the effects of omega-3 supplements on 
emotional experiences.  After giving informed consent, each participant was tested 
individually.  All participants first completed the OQuESA, BDI-II, and demographics 
form.  After completing the questionnaires, participants who qualified for the study were 
given a negative mood induction similar in procedure to that used by Ingram, Bernet, and 
McLaughlin (1994).  Specifically, participants were asked to reflect on a sad event in 
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their lives while listening to sad music for a period of eight minutes.  Immediately 
following the mood induction, participants completed the MAACL-R questionnaire.  
After completing the mood induction and the MAACL-R, participants were 
randomly assigned via a random number generator to the omega-3 group or the placebo 
group.  The participants assigned to the omega-3 group were given 3 weeks’ worth of 
omega-3 fish oil supplements.  The assigned daily dose of omega-3 fatty acids was 2,126 
mg (800 mg EPA and 400 mg DHA).  Participants were informed that they could be 
assigned omega-3 supplements or a pill placebo.  Participants were instructed to take two 
pills per day.  Participants in the placebo group were given 3 weeks’ worth of mineral oil 
placebo pills that closely mimic the appearance of omega-3 supplements.  Instructions for 
the placebo group were identical to those for the omega-3 group.  Participants were also 
given notecards with the dates for the next three weeks written on them.  Participants 
were instructed to text or email a picture of themselves taking the pills with the correct 
date card to a secure email address each day to be used as a means of documenting 
protocol adherence.  They were also instructed to include a rating each day on a scale 
from 1 to 10 of the “most positive” their mood was that day, and a separate rating on a 
scale from -1 to -10 on the “most negative” their mood was that day. 
After three weeks, participants returned to the lab.  Participants first completed 
the OQuESA and BDI-II.  After completing the questionnaires, all participants were 
given a negative mood induction.  Participants were asked to reflect on a sad event in 
their lives while listening to sad music for a period of eight minutes.  Immediately 
following the mood induction, participants completed the MAACL-R questionnaire.  
Before leaving the lab, all participants were verbally debriefed about the purpose of the 
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study.  Questionnaires from the second experimental session were analyzed for 
differences in emotional blunting between groups.  
Results 
Only individuals who returned for the second experimental session and completed 
16 or more days of the adherence check were included in the analyses.  Out of 181 
participants who completed the first experimental session, 43 participants did not return 
for the second experimental session and 21 participants did not complete 16 or more days 
of the adherence check.  In total, 117 participants, 58 participants in the placebo group 
and 59 participants in the omega-3 group, were included.  Both groups had an adherence 
rate of approximately 95% with respect to the daily ingestion of omega-3 and placebo 
capsules, respectively.     
Contrary to the study hypothesis, a one-way analysis of variance (ANOVA) 
revealed that scores did not differ significantly between the omega-3 group (M = 4.97, SD 
= 4.23) and the placebo group (M = 4.84, SD = 5.02) on the MAACL-R dysphoria scale 
following the study’s negative mood induction procedure [F(1,115) = 0.02; p = 0.888].   
In order to evaluate hypothesized differences between the omega-3 group and 
placebo group in emotional intensity and variability over the course of the 3-week study, 
I employed a multilevel (latent growth curve) analysis, a strategy particularly well suited 
to evaluating between-group differences in the trajectory of construct variability.  The 
model intercepts of the two groups were not significantly different on Day 1, indicating 
the absence of any preexisting differences between groups on emotional variability (z = -
0.26, p = 0.945).  Further, there was no significant difference between the model’s slope 
estimates of the two groups over the 3-week assessment, which suggests that variability 
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in emotional intensity did not significantly differ between the two groups over the course 
of the study (z = 1.19, p = 0.361). 
Because OQuESA total scores were positively skewed in the study sample, they 
did not meet the requisite assumptions for use in ANOVA modeling.  Accordingly, 
negative binomial regression was selected as a more appropriate strategy to evaluate 
potential differences in OQuESA scores between the omega-3 and placebo groups.  The 
omega-3 group (M = 37.88, SD =13.65) reported significantly more emotional blunting 
than did the placebo group (M = 33.02, SD = 9.93) on the OQuESA (  = 1.15, p < 0.05).  
The Cohen’s effect size estimate for this difference (d = 0.41) is considered a moderate 
effect.   
Three of the four subscales of the OQuESA were also found to differ significantly 
between the two groups: general reduction of emotions was greater in the omega-3 group 
(M = 9.07, SD = 3.58) than the placebo group (M = 7.31, SD = 2.78) (F = 5.72, p = 
0.018), reduction in positive emotions was greater in the omega-3 group (M = 7.22, SD = 
3.33) than the placebo group (M = 6.16, SD = 2.12) (F = 4.241, p = 0.042), and not 
caring was greater in the omega-3 group (M = 6.85, SD = 2.56) than the placebo group 
(M = 5.97, SD = 2.04) (F = 4.236, p = 0.042).  There was no significant difference on 
emotional detachment from others between the omega-3 group (M = 7.27, SD = 3.62) and 
the placebo group (M = 6.95, SD = 3.14) (F = .265, p = .608).   
Discussion 
The main aim of the present research was to investigate the degree to which 
omega-3 supplementation – an evidence-based treatment for major depressive disorder 
(Parker et al., 2006; Ross, Seguin, & Sieswerda, 2007; Martins, 2009; Sublette, Ellis, 
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Geant & Mann, 2011) – has the potential to induce emotional blunting.  Such blunting 
has been commonly observed in SSRI therapy (Opbroek et al., 2002), and in light of the 
potential similarities between SSRIs and omega-3 supplements in their facilitation of 
increased cerebral serotonergic signaling, it was hypothesized that omega-3 supplements 
may have similar effects on the intensity of emotional experience. Notably, there has 
been no published research to date directly germane to this question.   
As hypothesized, study participants in the omega-3 condition reported 
significantly more emotional blunting than did those in the placebo condition following 3 
weeks of supplementation.  Specifically, participants who took omega-3s scored 
approximately 0.41 standard deviations higher (Cohen’s d) than those in the placebo 
group on the study’s principal measure of emotional blunting, the Oxford Questionnaire 
of the Emotional Side-effects of Antidepressants (OQuESA).  This moderate-sized 
between-group difference was roughly the equivalent of responding I agree rather than I 
agree a little on any 5 of the OQuESA’s 31 items (e.g., “I don’t look forward to things 
with eager anticipation”; “My emotions lack intensity”; “I don’t have much sympathy for 
other people”).  Importantly, the observed emotional blunting effect of omega-3s is 
modest in comparison with the very large effect that has been reported among depressed 
individuals receiving SSRI pharmacotherapy (Opbroek et al., 2002).    
Participants in the omega-3 condition also scored significantly higher on three of 
the OQuESA’s four subscales: general reduction of emotions, reduction in positive 
emotions, and not caring.  There was, however, no significant difference between groups 
on emotional detachment from others.  It is possible, therefore, that omega-3 supplements 
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have a more noticeable effect on the subjective experience of emotional intensity than on 
the specific quality of one’s emotional connection to others. 
Interestingly, no evidence of emotional blunting in association with omega-3s was 
observed in the study’s experimental induction of dysphoric mood.  While it is possible 
that omega-3s simply exert no pronounced effect in blunting transient dysphoria, this 
particular null result may also be a mere artifact of the mood rating scale (the MAACL-
R) employed in the study’s mood-induction procedure.   The MAACL-R, although a 
widely used measure in the experimental literature (Lubin, Swearngin & Zuckerman, 
1997), only provides a checklist of various possible emotional states, without assessing 
the intensity of each such emotion.  
The study’s multilevel latent growth curve analysis of daily emotional intensity 
during the 3 weeks of supplementation also revealed no significant between-group 
differences.  In other words, participants in both groups exhibited equal variability in the 
average intensity of both positive and negative emotions over the course of the study.  
However, it should be noted that the sample size was not sufficient to reliably detect 
small-to-moderate effects within a multilevel model, so this null result should be 
interpreted with some caution. 
Taken together, the study’s three principal tests of emotional blunting in the 
context of omega-3 supplementation suggest that healthy individuals taking omega-3 
supplements may experience moderate blunting in a limited subset of emotion-linked 
domains.  Specifically, participant responses to the primary self-report questionnaire 
measure (OQuESA) indicate a significant reduction in the perceived intensity of both 
positive and negative moods, along with a reduced intensity of caring, following 3 weeks 
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of omega-3 supplementation.  But this blunting effect was modest, and it was not, in fact, 
observed during the study’s experimental manipulation of dysphoric mood.   
So, how might we best evaluate the clinical significance – if any – of such a 
moderate level of omega-3-induced emotional blunting?  Certainly, some blunting of 
negative mood could be desirable for individuals suffering from major depression or 
other painful mood disorders.  On the other hand, the blunting of positive emotions and 
reduced caring are potentially harmful side effects that would be regarded as undesirable, 
regardless of the magnitude of the blunting effect.  Moreover, many of those who 
supplement with omega-3s may have limited awareness of their own emotional blunting, 
inasmuch as no one is presently on the lookout for this potential side effect.  Unlike 
antidepressant medication, omega-3 supplements do not require a prescription, and they 
can be taken without any monitoring by a healthcare provider.  Many individuals take 
omega-3 supplements for treatment or prevention of depressive symptoms, as well as 
myriad reasons unrelated to psychiatric concerns, e.g., to protect heart health, to combat 
inflammatory conditions, to increase eye moisture, etc.  Accordingly, those taking 
omega-3 supplements should be informed about their potential emotional blunting effect 
in order to increase awareness, and to allow for informed decisions regarding omega-3 
use.       
There are several notable limitations of the current study.  First, the use of self-
report questionnaires is vulnerable to response bias.  Although most of the participants 
were not familiar with the concept of emotional blunting, a variety of potential biases in 
responses could have occurred due to the use of self-report questionnaires.  For example, 
participants may conceivably report more emotional blunting when they believe they are 
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in the omega-3 condition and less emotional blunting when they believe they are in the 
placebo condition.  We did not assess participants’ beliefs about their group assignment. 
  Additionally, as noted previously, the use of a healthy, predominantly female 
undergraduate sample may limit the generalizability of study results to other populations.  
In order to help ensure a high level of adherence, this study also used a dose of omega-3 
supplementation that was slightly lower than the commonly recommended dose for 
treating depression.  It is possible that a higher dose of omega-3s would have yielded 
larger mood-related effects of supplementation, and may thereby have influenced the 
outcome of some study analyses.   
It should also be noted that the study was only three weeks in duration, which is 
shorter than most published trials of omega-3 supplementation for depression, as well as 
virtually all trials of antidepressant medication.  A study of longer duration could 
conceivably detect additional mood-related effects that take a longer period of time to 
develop.  Finally, the adherence check for the study required participants to send pictures 
of themselves taking the capsules each day.  Although this methodology is superior to the 
use of a mere self-report questionnaire to assess protocol adherence, the use of biological 
measures – e.g., blood assays of omega-3 composition – would doubtless provide a more 
accurate assessment of adherence.      
Because this is the first study investigating the effects of omega-3 supplements on 
emotional blunting, additional studies should be conducted to attempt replication of these 
results.  Additional studies could also be conducted to determine dose-specific effects of 
omega-3 supplements on emotional blunting.  The current study used an 800 mg daily 
dose of EPA – the antidepressant molecular form of omega-3 – which is slightly below 
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the commonly accepted antidepressant dosing range of 1000 mg per day.  Due to the 
continued lack of agreement in the literature about the biochemical mechanisms of 
omega-3 supplements responsible for their antidepressant effects, it follows that similar 
studies attempting to parcel out these effects should be conducted assessing emotional 
blunting.  These studies may also help to illuminate the connection between 
antidepressant effects and emotional blunting, and the potential similarities between the 
effects of SSRIs and omega-3 supplements on the brain’s emotion-regulation systems.   
Future studies could also use questionnaires assessing a broader range of 
emotional experiences over time to assess daily variability in emotional reactivity, and 
could investigate emotional reaction to mood inductions with a questionnaire that would 
allow participants to report intensity of emotions such as the Profile of Mood States 
(POMS).  Future studies should also investigate additional experimental methods in 
addition to self-report questionnaires to assess the development of emotional blunting. 
Finally, future studies should also investigate this phenomenon in populations other than 
healthy college students, including those with depression, anxiety, or other psychological 
disorders. 
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